Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre V Hirayama

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Blood|January 18, 2024
CD19 occupancy may drive CARs furtherAlexandre V Hirayama, Marie Bleakley
Blood|February 27, 2025
Competition for CD19 binding may accelerate CAR efficacyAlexandre V Hirayama, Marie Bleakley
American Journal of Hematology|February 21, 2019
Toxicities of CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Cameron J Turtle
Bone Marrow Transplantation|December 27, 2022
CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic reviewAndrew J Portuguese, Jordan Gauthier, Scott S Tykodi, et al.
European Journal of Haematology|August 1, 2023
Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor-T cell therapyCecilia C S Yeung, David W Woolston, Vicky Wu, et al.
Blood Advances|October 19, 2021
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapyKrishna R Juluri, Qian Vicky Wu, Jenna Voutsinas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 17, 2019
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T CellsAna Cordeiro, Evandro D Bezerra, Alexandre V Hirayama, et al.
Hemasphere|August 8, 2024
PD-L1<sup>+</sup> macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacyAlexandre V Hirayama, Jocelyn H Wright, Kimberly S Smythe, et al.
The Lancet. Respiratory Medicine|January 18, 2021
Assessing the importance of interleukin-6 in COVID-19 - Authors' replyDaniel E Leisman, Lukas Ronner, Rachel Pinotti, et al.
The Lancet. Respiratory Medicine|October 19, 2020
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromesDaniel E Leisman, Lukas Ronner, Rachel Pinotti, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Blood|January 18, 2024
CD19 occupancy may drive CARs furtherAlexandre V Hirayama, Marie Bleakley
Blood|February 27, 2025
Competition for CD19 binding may accelerate CAR efficacyAlexandre V Hirayama, Marie Bleakley
American Journal of Hematology|February 21, 2019
Toxicities of CD19 CAR-T cell immunotherapyAlexandre V Hirayama, Cameron J Turtle
Bone Marrow Transplantation|December 27, 2022
CD19 CAR-T therapy in solid organ transplant recipients: case report and systematic reviewAndrew J Portuguese, Jordan Gauthier, Scott S Tykodi, et al.
European Journal of Haematology|August 1, 2023
Abnormal bone marrow findings in patients following treatment with chimeric antigen receptor-T cell therapyCecilia C S Yeung, David W Woolston, Vicky Wu, et al.
Blood Advances|October 19, 2021
Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapyKrishna R Juluri, Qian Vicky Wu, Jenna Voutsinas, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 17, 2019
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T CellsAna Cordeiro, Evandro D Bezerra, Alexandre V Hirayama, et al.
Hemasphere|August 8, 2024
PD-L1<sup>+</sup> macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacyAlexandre V Hirayama, Jocelyn H Wright, Kimberly S Smythe, et al.
The Lancet. Respiratory Medicine|January 18, 2021
Assessing the importance of interleukin-6 in COVID-19 - Authors' replyDaniel E Leisman, Lukas Ronner, Rachel Pinotti, et al.
The Lancet. Respiratory Medicine|October 19, 2020
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromesDaniel E Leisman, Lukas Ronner, Rachel Pinotti, et al.
Pageof 4